Literature DB >> 16328539

Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter.

Francois Cachat, Daniel Bardy, Claudine Durussel, Ermindo Di Paolo.   

Abstract

Alteplase has been shown to be effective in preventing central venous access clotting in patients on hemodialysis. Because of a high phosphorus content in its excipient, it can inadvertently contaminate blood samples, leading the physician in care of the patient to erroneously increase dialysis time or change diet in order to control the pseudo-hyperphosphatemia.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16328539     DOI： 10.1007/s00467-005-2088-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  8 in total

1.  Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath.

Authors:  P Schenk; A R Rosenkranz; G Wölfl; W H Hörl; O Traindl
Journal:  Am J Kidney Dis       Date:  2000-01       Impact factor: 8.860

2.  Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter.

Authors:  Cindy L Ball; Kathleen Tobler; B Catherine Ross; M Ruth Connors; Martha E Lyon
Journal:  Clin Chem Lab Med       Date:  2004-01       Impact factor: 3.694

3.  Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient.

Authors:  Kevin D McBryde; Jennifer Wilcox; Kanwal K Kher
Journal:  Pediatr Nephrol       Date:  2005-06-18       Impact factor: 3.714

4.  A survey of permanent double lumen catheters in hemodialysis patients.

Authors:  G Dunea; L Domenico; P Gunnerson; F Winston-Willis
Journal:  ASAIO Trans       Date:  1991 Jul-Sep

5.  Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters.

Authors:  P Daeihagh; J Jordan; J Chen; M Rocco
Journal:  Am J Kidney Dis       Date:  2000-07       Impact factor: 8.860

6.  Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin.

Authors:  J M Mandry; M R Posner; J R Tucci; C Eil
Journal:  Cancer       Date:  1991-09-01       Impact factor: 6.860

7.  Spurious hyperphosphatemia due to hyperlipidemia.

Authors:  D J Leehey; J T Daugirdas; T S Ing; R W Reid
Journal:  Arch Intern Med       Date:  1985-04

8.  Pseudohyperphosphataemia incidence in an automatic analyzer.

Authors:  A M Cohen; A Magazanik; E van-der Lijn; P Shaked; H Levinsky
Journal:  Eur J Clin Chem Clin Biochem       Date:  1994-07
  8 in total
  2 in total

1.  Spurious hyperphosphatemia in patients on hemodialysis with catheters.

Authors:  Brigitte Schiller; Bhupinder Virk; Martin Blair; Amy Wong; John Moran
Journal:  Am J Kidney Dis       Date:  2008-06-05       Impact factor: 8.860

2.  Pseudohyperphosphatemia due to contamination with heparin: A case for caution.

Authors:  S Senthilkumaran; R G Menezes; S Jayaraman; P Thirumalaikolundusubramanian
Journal:  Indian J Nephrol       Date:  2014-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.